Drug induced liver injury – a 2023 update

Allison, Rebecca; Guraka, Asha; Shawa, Isaac Thom; Tripathi, Gyan; Moritz, Wolfgang; Kermanizadeh, Ali

doi:10.1080/10937404.2023.2261848

Cited by 26 publications

(11 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most cases resolve spontaneously; however, some CAM-liver injuries can progress to chronic liver injury, ALF, or ACLF, with a high rate of mortality in the absence of a timely liver transplant. 55 , 56 …”

Section: Clinical Presentation Assessment and Outcomesmentioning

confidence: 99%

Complementary and alternative medicines and liver disease

Philips,

Theruvath,

Ravindran

et al. 2024

Hepatology Communications

View full text Add to dashboard Cite

Complementary and alternative medicines (CAM) include conventional medical treatments. Patients worldwide use CAM at alarming rates; thus, reports of CAM-related DILI have been on the rise. The clinical presentations include asymptomatic liver test abnormalities, acute hepatitis with or without jaundice, acute cholestatic liver disease (bland or with hepatitis), acute liver failure, severe hepatitis with features of portal hypertension, and acute decompensation of known or unknown cirrhosis that can lead to acute-on-chronic liver failure. Acute hepatitis with or without necrosis, hepatocellular and canalicular cholestasis, herb-induced or CAM-triggered autoimmune hepatitis, granulomatous hepatitis, severe steatohepatitis, and vanishing bile duct syndrome are common liver biopsy findings in CAM-DILI. The presence of preexisting liver disease predicts severe liver injury, risk of progression to liver failure, and decreased transplant-free survival in patients with CAM-DILI. This review discusses global epidemiology and trends in CAM-DILI, clinical presentation, assessment and outcomes, commonly emerging threats in the context of hepatotoxic herbs, pragmatic assessment of “liver beneficial” herbs and health care myths, patient communication, regulatory framework, and future directions on research in CAM.

show abstract

Section: Clinical Presentation Assessment and Outcomesmentioning

confidence: 99%

Complementary and alternative medicines and liver disease

Philips,

Theruvath,

Ravindran

et al. 2024

Hepatology Communications

View full text Add to dashboard Cite

show abstract

“…Indeed, idiosyncratic DILI (iDILI) is usually dose-independent and occurs in only a small fraction of subjects. Furthermore, there is evidence that most iDILI cases are immune-mediated, suggesting that its occurrence may also depend on the age and sex of the subject as these non-genetic factors influence the immune cell landscape ( Uetrecht, 2019 ; Huang et al, 2021 ; Allison et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury: the case of troglitazone

Roux,

Cherradi,

Duong

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Idiosyncratic drug-induced liver injury (iDILI) is a major concern in drug development because its occurrence is unpredictable. Presently, iDILI prediction is a challenge, and cell toxicity is observed only at concentrations that are much higher than the therapeutic doses in preclinical models. Applying a proprietary cell educating technology, we developed a person-dependent spheroid system that contains autologous educated immune cells that can detect iDILI risk at therapeutic concentrations. Integrating this system into a high-throughput screening platform will help pharmaceutical companies accurately detect the iDILI risk of new molecules de-risking drug development.

show abstract

“…Drug-induced liver injury (DILI) is the most common cause of acute liver failure in developed countries [ 1 ]. The diagnosis, treatment, and prevention of DILI remain a challenge [ 2 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Lansoprazole Ameliorates Isoniazid-Induced Liver Injury

Wakai,

Shiromizu,

Otaki

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Isoniazid is a first-line drug in antitubercular therapy. Isoniazid is one of the most commonly used drugs that can cause liver injury or acute liver failure, leading to death or emergency liver transplantation. Therapeutic approaches for the prevention of isoniazid-induced liver injury are yet to be established. In this study, we identified the gene expression signature for isoniazid-induced liver injury using a public transcriptome dataset, focusing on the differences in susceptibility to isoniazid in various mouse strains. We predicted that lansoprazole is a potentially protective drug against isoniazid-induced liver injury using connectivity mapping and an adverse event reporting system. We confirmed the protective effects of lansoprazole against isoniazid-induced liver injury using zebrafish and patients’ electronic health records. These results suggest that lansoprazole can ameliorate isoniazid-induced liver injury. The integrative approach used in this study may be applied to identify novel functions of clinical drugs, leading to drug repositioning.

show abstract

Drug induced liver injury – a 2023 update

Cited by 26 publications

References 142 publications

Complementary and alternative medicines and liver disease

Complementary and alternative medicines and liver disease

Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury: the case of troglitazone

Lansoprazole Ameliorates Isoniazid-Induced Liver Injury

Contact Info

Product

Resources

About